BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9706342)

  • 1. [Importance of the study of the expression of MIB-1 (Ki-67) for the diagnosis of endocervical glandular lesions].
    Leteurtre E; Boman F; Farine MO; Leroy JL; Gosselin B
    Ann Pathol; 1998 Jul; 18(3):172-7. PubMed ID: 9706342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocervical glandular lesions: a diagnostic approach combining a semi-quantitative scoring method to the expression of CEA, MIB-1 and p16.
    Pavlakis K; Messini I; Athanassiadou S; Kyrodimou E; Pandazopoulou A; Vrekoussis T; Stathopoulos EN
    Gynecol Oncol; 2006 Dec; 103(3):971-6. PubMed ID: 16876235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical staining for Ki-67 antigen, carcinoembryonic antigen, and p53 in the differential diagnosis of glandular lesions of the cervix.
    Cina SJ; Richardson MS; Austin RM; Kurman RJ
    Mod Pathol; 1997 Mar; 10(3):176-80. PubMed ID: 9071723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of p16ink4a, ProEX C, and Ki-67 for the diagnosis of glandular dysplasia and adenocarcinoma of the cervix uteri.
    Negri G; Bellisano G; Carico E; Faa G; Kasal A; Antoniazzi S; Egarter-Vigl E; Piccin A; Dalla Palma P; Vittadello F
    Int J Gynecol Pathol; 2011 Jul; 30(4):407-13. PubMed ID: 21623205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma.
    Rabban JT; McAlhany S; Lerwill MF; Grenert JP; Zaloudek CJ
    Am J Surg Pathol; 2010 Feb; 34(2):137-46. PubMed ID: 20061933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of epithelial-specific antigen in uterine cervix with endocervical glandular dysplasia.
    Umezaki K; Sanezumi M; Okada H; Okamura A; Tsubra A; Kanazaki H
    Gynecol Oncol; 1997 Sep; 66(3):393-8. PubMed ID: 9299251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of MiB-1 staining in smears with atypical glandular cells.
    Boon ME; Vinkestein A; van Binsbergen-Ingelse A; van Haaften C
    Diagn Cytopathol; 2004 Aug; 31(2):77-82. PubMed ID: 15282717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p16 expression in the female genital tract and its value in diagnosis.
    O'Neill CJ; McCluggage WG
    Adv Anat Pathol; 2006 Jan; 13(1):8-15. PubMed ID: 16462152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
    Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
    Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma.
    McCluggage WG; Jenkins D
    Int J Gynecol Pathol; 2003 Jul; 22(3):231-5. PubMed ID: 12819388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathologic aspects in microglandular hyperplasia of endocervix.
    Florescu M; Simionescu C; Georgescu CV; Marinescu M
    Rom J Morphol Embryol; 1999-2004; 45():181-4. PubMed ID: 15847393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superficial (early) endocervical adenocarcinoma in situ: a study of 12 cases and comparison to conventional AIS.
    Witkiewicz A; Lee KR; Brodsky G; Cviko A; Brodsky J; Crum CP
    Am J Surg Pathol; 2005 Dec; 29(12):1609-14. PubMed ID: 16327433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal expression of sex steroid receptors and cell cycle-related molecules in adenocarcinoma in situ of the uterine cervix.
    Lu X; Shiozawa T; Nakayama K; Toki T; Nikaido T; Fujii S
    Int J Gynecol Pathol; 1999 Apr; 18(2):109-14. PubMed ID: 10202666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia.
    Cameron RI; Maxwell P; Jenkins D; McCluggage WG
    Histopathology; 2002 Oct; 41(4):313-21. PubMed ID: 12383213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of p16INK4a, CEA, Ki67, P53 and ER/PR in the differential diagnosis of benign, premalignant, and malignant glandular lesions of the uterine cervix and their relationship with Silverberg scoring system for endocervical glandular lesions.
    Liang J; Mittal KR; Wei JJ; Yee H; Chiriboga L; Shukla P
    Int J Gynecol Pathol; 2007 Jan; 26(1):71-5. PubMed ID: 17197900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upgrading unsatisfactory cervical smears with the MiB-1 method.
    Boon ME; Kleinschmidt-Guy ED; Wijsman-Grootendorst A; Hoogeveen MM
    Diagn Cytopathol; 1996 Nov; 15(4):270-6. PubMed ID: 8982579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biometric research in the diagnosis of precancerous states and endocervical cancer].
    Novik VI; Agroskin LS; Papaian GV; Solov'eva LV
    Arkh Patol; 1989; 51(12):45-50. PubMed ID: 2629663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal deviation endocervical adenocarcinoma: clinical and histologic features, immunohistochemical staining for carcinoembryonic antigen, and differentiation from confusing benign lesions.
    Michael H; Grawe L; Kraus FT
    Int J Gynecol Pathol; 1984; 3(3):261-76. PubMed ID: 6500801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenocarcinoma in situ of the cervix: management and outcome.
    Azodi M; Chambers SK; Rutherford TJ; Kohorn EI; Schwartz PE; Chambers JT
    Gynecol Oncol; 1999 Jun; 73(3):348-53. PubMed ID: 10366458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.